Linked Life Data

19276276

Source:http://linkedlifedata.com/resource/pubmed/id/19276276

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2009-3-17
pubmed:abstractText
In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
15
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1891-7
pubmed:dateRevised
2011-5-4
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Considerations for the use of imaging tools for phase II treatment trials in oncology.
pubmed:affiliation
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. shankarl@mail.nih.gov
pubmed:publicationType
Journal Article, Review